CN103748074A - 芳氧基喹啉类衍生物及其治疗用途 - Google Patents

芳氧基喹啉类衍生物及其治疗用途 Download PDF

Info

Publication number
CN103748074A
CN103748074A CN201280028921.8A CN201280028921A CN103748074A CN 103748074 A CN103748074 A CN 103748074A CN 201280028921 A CN201280028921 A CN 201280028921A CN 103748074 A CN103748074 A CN 103748074A
Authority
CN
China
Prior art keywords
yue
epoxides
phenyl
epoxide
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201280028921.8A
Other languages
English (en)
Other versions
CN103748074B8 (zh
CN103748074B (zh
Inventor
陈从喜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TIANJIN LONGBOGEN PHARMACEUTICAL CO Ltd
Nanchang Hongyi Pharmaceutical Co Ltd
Original Assignee
Tianjin Longbogene Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Longbogene Pharmaceutical Co ltd filed Critical Tianjin Longbogene Pharmaceutical Co ltd
Priority to CN201280028921.8A priority Critical patent/CN103748074B8/zh
Publication of CN103748074A publication Critical patent/CN103748074A/zh
Application granted granted Critical
Publication of CN103748074B publication Critical patent/CN103748074B/zh
Publication of CN103748074B8 publication Critical patent/CN103748074B8/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一类芳氧基喹啉类衍生物，该化合物为式(Ⅰ)化合物或其药学上可接受的盐或溶剂合物，R1、R2、R3、R4、m、n、X、Z、Ar的定义详见说明书。此外，本发明还公开了以该化合物或其盐类为活性成分的药物及用途，主要用于治疗蛋白酪氨酸激酶受体尤其是与c-Met，VEGFR等有关的疾病。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201280028921.8A 2011-06-17 2012-06-15 芳氧基喹啉类衍生物及其治疗用途 Active CN103748074B8 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280028921.8A CN103748074B8 (zh) 2011-06-17 2012-06-15 芳氧基喹啉类衍生物及其治疗用途

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN2011101632151 2011-06-17
CN201110163215 2011-06-17
CN201110163215.1 2011-06-17
CN2011102520350 2011-08-30
CN201110252035.0 2011-08-30
CN201110252035 2011-08-30
CN201110397142 2011-12-05
CN2011103971422 2011-12-05
CN201110397142.2 2011-12-05
PCT/CN2012/077016 WO2012171487A1 (zh) 2011-06-17 2012-06-15 芳氧基喹啉类衍生物及其治疗用途
CN201280028921.8A CN103748074B8 (zh) 2011-06-17 2012-06-15 芳氧基喹啉类衍生物及其治疗用途

Publications (3)

Publication Number Publication Date
CN103748074A true CN103748074A (zh) 2014-04-23
CN103748074B CN103748074B (zh) 2016-05-18
CN103748074B8 CN103748074B8 (zh) 2016-09-14

Family

ID=47356551

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280028921.8A Active CN103748074B8 (zh) 2011-06-17 2012-06-15 芳氧基喹啉类衍生物及其治疗用途

Country Status (2)

Country Link
CN (1) CN103748074B8 (zh)
WO (1) WO2012171487A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9957233B1 (en) 2016-08-05 2018-05-01 Calitor Sciences, Llc Process for preparing substituted quinolin-4-ol compounds
CN107778285A (zh) * 2016-08-24 2018-03-09 南昌弘益药业有限公司 一类喹啉类新化合物
CN107778287A (zh) * 2016-08-26 2018-03-09 南昌弘益药业有限公司 作为酪氨酸蛋白激酶抑制剂的一类化合物
CN108329298A (zh) * 2017-01-17 2018-07-27 南昌弘益药业有限公司 一类喹啉类新化合物制备方法
CN108623565A (zh) * 2017-03-23 2018-10-09 南昌弘益药业有限公司 一种化合物的制备方法
CN109824587A (zh) * 2017-11-23 2019-05-31 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂xjf007及其中间体的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239576A1 (en) * 2009-03-21 2010-09-23 Ning Xi Amino ester derivatives, sailts thereof and methods of use
CN102093421A (zh) * 2011-01-28 2011-06-15 广州盈升生物科技有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408411A (zh) * 2011-09-19 2012-04-11 广州盈升生物科技有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239576A1 (en) * 2009-03-21 2010-09-23 Ning Xi Amino ester derivatives, sailts thereof and methods of use
CN102093421A (zh) * 2011-01-28 2011-06-15 广州盈升生物科技有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408411A (zh) * 2011-09-19 2012-04-11 广州盈升生物科技有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用

Also Published As

Publication number Publication date
WO2012171487A1 (zh) 2012-12-20
CN103748074B8 (zh) 2016-09-14
CN103748074B (zh) 2016-05-18

Similar Documents

Publication Publication Date Title
CN103748074A (zh) 芳氧基喹啉类衍生物及其治疗用途
ES2751608T3 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibitoria para las proteínas quinasas
CN105431436B (zh) 吡咯并[2,3‑d]嘧啶衍生物，它们的制备方法和它们作为激酶抑制剂的用途
ES2543320T3 (es) Acetamidas sustituídas con N-(hetero)aril,2-(hetero)arilo para uso como moduladores de señalización de Wnt
CA2620534C (en) Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
CN102977014B (zh) 新的喹啉类化合物及其用途
CN103270023A (zh) 作为用于治疗疾病诸如癌症的nampt 抑制剂的4-{[(吡啶-3-基-甲基)氨基羰基]氨基}苯-砜衍生物
CN102260263A (zh) 一类二苯胺基嘌呤衍生物及制备方法和医药用途
CN101506214A (zh) 作为parp抑制剂的吡唑并喹唑啉酮
IL213141A (en) Dihydroindane amides for use in regulating protein kinase activity
TW200825081A (en) Compositions and methods for modulating C-KIT and PDGFR receptors
MX2007007704A (es) Compuestos heterociclicos biciclicos novedosos, procesos para su preparacion y composiciones que los contienen.
CA2932831A1 (en) Substituted nicotinamide derivatives as kinase inhibitors
CN104703983A (zh) N2,n4-双(4-(哌嗪-1-基)苯基)嘧啶-2,4-二胺衍生物或其药学上可接受的盐,及以其作为活性成分用于预防或治疗癌症的组合物
Vasbinder et al. Discovery and optimization of a novel series of potent mutant B-RafV600E selective kinase inhibitors
CN104211686A (zh) 喹啉类衍生物及其治疗用途
CN104470934A (zh) 蛋白激酶抑制剂
WO2023279938A1 (zh) 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用
CA2853062A1 (en) Pyridine- sulfoximines as tyrosine kinase inhibitors
CN102300847A (zh) Ppar激动剂组合物及其使用方法
WO2022148243A1 (zh) 一种嘧啶类小分子化合物及其应用
CN106478621A (zh) 喹啉或喹唑啉类衍生物、制备方法及其应用
CN110054584B (zh) 1-芳基-3-{4-[(吡啶-2-基甲基)硫基]苯基}脲类化合物及应用
CN103396417B (zh) 新型羟肟酸衍生物及其医疗应用
CN102633812B (zh) 噁唑酮并喹唑啉衍生物、制备方法及用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
CB03 Change of inventor or designer information

Inventor after: Zhang Wenyan

Inventor after: Zhao Yan

Inventor after: Xu Jun

Inventor after: Peng Hong

Inventor after: Tao Lin

Inventor after: Zhang Xiaoli

Inventor after: Zhao Yinying

Inventor after: Wang Xiaoxia

Inventor after: Li Yonghua

Inventor after: Zou Yang

Inventor before: Chen Congxi

COR Change of bibliographic data
TR01 Transfer of patent right

Effective date of registration: 20160513

Address after: 330096 No. 789 torch street, hi tech Zone, Jiangxi, Nanchang

Patentee after: Nanchang Helioeast Pharmaceutical Co., Ltd.

Patentee after: TIANJIN LONGBOGEN PHARMACEUTICAL CO., LTD.

Address before: 300457, Tianjin Binhai New Area, Tianjin Development Zone, Fourth Avenue, No. 80, Tian Da Science and Technology Park, A1 building, room 219, room two

Patentee before: TIANJIN LONGBOGEN PHARMACEUTICAL CO., LTD.

C53 Correction of patent of invention or patent application
CI01 Publication of corrected invention patent application

Correction item: Patentee|Address|Patentee|Inventor

Correct: Nanchang helioeast Pharmaceutical Co. Ltd. |Jiangxi 330096 Nanchang torch hi tech Zone Street No. 789|TIANJIN LONGBOGEN PHARMACEUTICAL CO., LTD.|Zhang Wenyan|Xu Jun|Peng Hong|Tao Lin|Zhang Xiaoli|Zhao Yinying|Wang Xiaoxia|Li Yonghua|Zou Yang|Zhao Yan

False: Tianjin Longbo Gene Medicine Technology Co. Ltd. |Tianjin 300457 city of Tianjin Binhai New Area Development Zone Fourth Street No. 80 Big Science Park A1 building two room 219|Chen Congxi

Number: 20

Volume: 32

CI03 Correction of invention patent

Correction item: Patentee|Address|Patentee|Inventor

Correct: Nanchang helioeast Pharmaceutical Co. Ltd. |Jiangxi 330096 Nanchang torch hi tech Zone Street No. 789|TIANJIN LONGBOGEN PHARMACEUTICAL CO., LTD.|Zhang Wenyan|Xu Jun|Peng Hong|Tao Lin|Zhang Xiaoli|Zhao Yinying|Wang Xiaoxia|Li Yonghua|Zou Yang|Zhao Yan

False: Tianjin Longbo Gene Medicine Technology Co. Ltd.| Tianjin 300457 city of Tianjin Binhai New Area Development Zone Fourth Street No. 80 Big Science Park A1 building two room 219|Chen Congxi

Number: 20

Page: The title page

Volume: 32

ERR Gazette correction